WITHUS PHARMACEUTICAL Co., Ltd.
KKRX:3303506,530.00
KRW
-110.00
(-1.66%)
ISIN
KR7330350000
Return %
Stock
S&P 500
1Y
-2.25
14.39
3Y
-21.23
81.42
5Y
-41.17
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Dae-Young Sung
- Full Time Employees
- 220
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Jul 3, 2020
- Website
- withuspharm.com
- Similar Companies
- Business
- WITHUS PHARMACEUTICAL Co., Ltd. is a South Korea-based pharmaceutical manufacturing and development company primarily engaged in the research, production, and commercialization of ethical pharmaceuticals (ETC) and specialized contract development and manufacturing organization (CDMO) services. Founded in 2004 and headquartered in Seoul, South Korea, the company operates advanced research, development, and manufacturing facilities, including its primary production plant in Anseong, Gyeonggi-do. WITHUS PHARMACEUTICAL serves hospitals, clinics, and wholesale distribution networks across South Korea and select international markets. The company provides a comprehensive portfolio of generic and specialty prescription medications organized into distinct therapeutic categories, including: circulatory and cardiovascular system therapeutics, such as antihypertensive agents, hyperlipidemia therapies, and antiplatelet formulations; musculoskeletal and anti-inflammatory drugs, comprising non-steroidal anti-inflammatory drugs (NSAIDs), osteoarthritis treatments, and skeletal muscle relaxants; gastrointestinal and digestive system agents, such as proton pump inhibitors, gastritis treatments, and anti-ulcer medications; respiratory system formulations, including antihistamines, antitussives, and expectorants; central nervous system (CNS) agents for dementia, cognitive disorders, and peripheral neuropathy; and custom pharmaceutical manufacturing services, encompassing oral solid dosage forms (tablets, capsules, and film-coated formulations) and sterile injectables. In recent strategic and operational developments, WITHUS PHARMACEUTICAL has accelerated its expansion into advanced drug delivery systems (DDS) and high-barrier contract manufacturing. The company completed and operationalized a dedicated, state-of-the-art long-acting injectable microsphere manufacturing facility at its Anseong production complex to support commercial-scale production of sustained-release therapeutics. In strategic collaboration with partners including Inventage Lab and Daewoong Pharmaceutical, the company has advanced the manufacturing validation and scale-up pipelines for long-acting injectable depot formulations, notably long-acting dutasteride treatments for androgenic alopecia and benign prostatic hyperplasia. Additionally, WITHUS PHARMACEUTICAL has expanded its third-party CDMO service capabilities, securing contract production mandates for incremental modified drugs (IMDs) and combination oral therapies to diversify its revenue streams.